VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the fourth quarter and full year 2024 after market close on Tuesday, March 18, 2025.
VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming virtual KeyBanc Capital Markets Healthcare Forum.
VANCOUVER, Wash. and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Guggenheim Securities SMID Cap Biotech Conference in New York, NY.
Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. ABS-101 appears to be ABSI's main drug candidate for IBD. However, ABS-201 for hair loss and ABS-301 for solid tumors offer additional sizeable TAMs if successful. ABSI's AI models and wet lab data seem quite promising for discovering further antibodies that could be highly differentiated from other competitors.
Collaboration combines Owkin's novel AI target discovery and agentic AI expertise with Absci's leading AI de novo design models to accelerate the discovery and design of potential first-in-class therapeutics Collaboration combines Owkin's novel AI target discovery and agentic AI expertise with Absci's leading AI de novo design models to accelerate the discovery and design of potential first-in-class therapeutics
Collaboration leverages Absci's leading generative AI Drug Creation models to design a novel antibody Half-Life Extension (HLE) platform for animal health applications Collaboration leverages Absci's leading generative AI Drug Creation models to design a novel antibody Half-Life Extension (HLE) platform for animal health applications
Absci Corporation (NASDAQ:ABSI ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Alex Khan - VP, Finance and IR Sean McClain - Founder and CEO Zach Jonasson - CFO and Chief Business Officer Christian Stegmann - SVP of Drug Creation Conference Call Participants Srikripa Devarakonda – Truist Securities Brendan Smith - TD Cowen George Farmer – Scotiabank Vamil Divan - Guggenheim Securities Operator Good day and thank you for standing by. Welcome to the Absci Q3 2024 Business Update Conference Call.
Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under collaboration
VANCOUVER, Wash. and NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the third quarter before market open on Tuesday, November 12, 2024.
Absci Corporation's initiation of a phase 1 study using ABS-101 for the treatment of patients with IBD expected early 2025, with interim data to be released in the 2nd half of 2025. ABS-101 aims to differentiate itself with unique features like de novo antibody creation, multiparameter lead optimization, and reverse immunology, potentially offering superior potency and dosing flexibility. The global Crohn's Disease treatment market is expected to reach $17.80 billion by 2033.